Global Transplant Diagnostics Market is Poised to Grow at A CAGR of 6.5%

Date: 2015-08-20

“The global transplant diagnostics market is poised to grow at a CAGR of 6.5% during 2014-2019, and is expected to reach a value of ~645.0 Million in 2019. Although the mature markets (such as the U.S., Germany, France, and U.K.) hold larger shares in the transplant diagnostics market, the Asia-Pacific region is expected to grow at the highest CAGR in the forecast period. The growth of the transplant diagnostics market is driven by factors such as growing geriatric population, coupled with an increasing population base for chronic disease patients, technological advancement in the field of HLA typing, increased public-private investments to develop innovative HLA testing products, rising number of solid organ, soft tissue, and stem cell-based transplantation procedures across the world. However, factors such as high cost of PCR and NGS instruments and limited medical reimbursement available for transplantation procedures are restraining the growth of this market. Huge gap between number of organs donated and organ donations required annually across the globe is posing a significant challenge for the growth of the transplant diagnostics market.   

In this report, the global transplant diagnostics market has been segmented on the basis of type of technology (molecular and non-molecular assay), type of product (instruments, reagents and consumables, and software and services), type of end users (hospitals and transplant centers, research laboratories and academic institutes, and commercial service providers) and type of application (diagnostic and research applications). The molecular assay technology segment accounted for the largest share of the global transplant diagnostics market in 2014, followed by the non-molecular assay technology market. Factors such as technological advancements in the field of HLA typing, rising adoption of HLA typing in research and medical diagnosis, benefits offered by robotics in lab automation, and increasing installation base of PCR and NGS instruments are driving the growth of transplant diagnostics market.

Geographically, North America (comprising the U.S. and Canada) commands the largest share of the global transplant diagnostics market in 2014, followed by Europe. The transplant diagnostics market in the North America is primarily driven by factors such as increase in public and private funding for development of HLA typing technology, growing number of solid organ transplantation procedure, and continuous reduction in average cost of gene sequencing. However, financial constraints faced by market players are limiting the growth of the digital transplant diagnostics market in this region. The Asia-Pacific region is poised to grow at the highest CAGR during next five years, owing to factors such as increasing focus of global life science companies in emerging markets, growing public and private support to develop novel HLA typing technologies, and strengthening healthcare infrastructure across the region. 

The global transplant diagnostics market is moderately competitive with a various global as well as local market players. As of 2013, the global transplant diagnostics market was dominated by Thermo Fisher Scientific Inc. (U.S.), Immucor, Inc. (U.S.), Olerup Ssp Ab (Norway), Qiagen N.V. (Netherlands), Bio-Rad Laboratories Inc. (U.S.), and Abbott Laboratories Inc. (U.S.), which together accounted for ~89.0% of the market. New product launches, partnerships, agreements, and collaborations, and strategic acquisitions are the major strategies adopted by most of the market players to achieve growth in the global transplant diagnostics market.    

Categories

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample